TICAGRELOR vs PLACEBO: Number of Participants With Modified Rankin Scale (mRS) Score >1 at Visit 3
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.238 | 0.227 | 0.25 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.241 | 0.229 | 0.252 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.00274 | -0.0189 | 0.0134 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.989 | 0.924 | 1.06 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.985 | 0.901 | 1.08 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with the outcome on TICAGRELOR than on PLACEBO | 365 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | TICAGRELOR | Ticagrelor 180 mg day 1, followed by 90 mg twice daily day 2-30 | 1,282 | 5,386 | OG000 | ClinicalTrials.gov |
| Group 2 | PLACEBO | Placebo 180 mg day 1, followed by 90 mg twice daily day 2-30 | 1,284 | 5,333 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | Number of Participants With Modified Rankin Scale (mRS) Score >1 at Visit 3 | ClinicalTrials.gov |
| Description | The modified Rankin Scale (mRS) is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6, running from perfect health without symptoms to death.0 - No symptoms,1 - No significant disability. Able to carry out all usual activities, despite some symptoms. 2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3 - Moderate disability. Requires some help, but able to walk unassisted. 4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6 - Dead. | ClinicalTrials.gov |
| Time frame | Visit 3 (day 30-34) | ClinicalTrials.gov |
| Population | Full analysis set including all randomised patients. Patients with missing mRS score or missing covariates, NIHSS (National Institutes of Health Stroke Scale) score and history of stroke (yes/no), were excluded | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death | ClinicalTrials.gov |
| NCT number | NCT03354429 | ClinicalTrials.gov |
| Phases | PHASE3 | ClinicalTrials.gov |
| Conditions | Acute Ischaemic Stroke, Transient Ischaemic Attack | ClinicalTrials.gov |
| Interventions | Ticagrelor, Placebo | ClinicalTrials.gov |
| Lead sponsor | AstraZeneca | ClinicalTrials.gov |
| Results first posted | 2020-12-22 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT03354429?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.